WallStreetZenWallStreetZen

NASDAQ: CABA
Cabaletta Bio Inc Stock

$4.26-0.05 (-1.16%)
Updated Oct 4, 2024
CABA Price
$4.26
Fair Value Price
$4.60
Market Cap
$208.10M
52 Week Low
$3.47
52 Week High
$26.35
P/E
-2.23x
P/B
1.04x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$89.98M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$74M
Beta
1.07
Next Earnings
Nov 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

CABA Overview

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CABA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CABA ($4.26) is undervalued by 7.33% relative to our estimate of its Fair Value price of $4.60 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CABA ($4.26) is not significantly undervalued (7.33%) relative to our estimate of its Fair Value price of $4.60 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CABA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CABA due diligence checks available for Premium users.

Be the first to know about important CABA news, forecast changes, insider trades & much more!

CABA News

Valuation

CABA fair value

Fair Value of CABA stock based on Discounted Cash Flow (DCF)
Price
$4.26
Fair Value
$4.60
Undervalued by
7.33%
CABA ($4.26) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CABA ($4.26) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CABA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CABA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.23x
Industry
-113.8x
Market
26.83x

CABA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.04x
Industry
5.96x
CABA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CABA's financial health

Profit margin

Revenue
$0.0
Net Income
-$27.6M
Profit Margin
0%
CABA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$217.4M
Liabilities
$17.9M
Debt to equity
0.09
CABA's short-term assets ($206.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CABA's short-term assets ($206.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CABA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$20.8M
Investing
$23.7M
Financing
$379.0k
CABA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CABA vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CABA$208.10M-1.16%-2.23x1.04x
PYXS$208.66M+0.85%-2.85x1.23x
BDTX$211.89M+2.46%-2.50x1.91x
AMLX$212.42M+6.12%-1.28x0.81x
CADL$213.36M-0.89%-3.93x-21.40x

Cabaletta Bio Stock FAQ

What is Cabaletta Bio's quote symbol?

(NASDAQ: CABA) Cabaletta Bio trades on the NASDAQ under the ticker symbol CABA. Cabaletta Bio stock quotes can also be displayed as NASDAQ: CABA.

If you're new to stock investing, here's how to buy Cabaletta Bio stock.

What is the 52 week high and low for Cabaletta Bio (NASDAQ: CABA)?

(NASDAQ: CABA) Cabaletta Bio's 52-week high was $26.35, and its 52-week low was $3.47. It is currently -83.83% from its 52-week high and 22.73% from its 52-week low.

How much is Cabaletta Bio stock worth today?

(NASDAQ: CABA) Cabaletta Bio currently has 48,848,673 outstanding shares. With Cabaletta Bio stock trading at $4.26 per share, the total value of Cabaletta Bio stock (market capitalization) is $208.10M.

Cabaletta Bio stock was originally listed at a price of $10.00 in Oct 25, 2019. If you had invested in Cabaletta Bio stock at $10.00, your return over the last 4 years would have been -57.4%, for an annualized return of -19.21% (not including any dividends or dividend reinvestments).

How much is Cabaletta Bio's stock price per share?

(NASDAQ: CABA) Cabaletta Bio stock price per share is $4.26 today (as of Oct 4, 2024).

What is Cabaletta Bio's Market Cap?

(NASDAQ: CABA) Cabaletta Bio's market cap is $208.10M, as of Oct 7, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Cabaletta Bio's market cap is calculated by multiplying CABA's current stock price of $4.26 by CABA's total outstanding shares of 48,848,673.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.